Sep 24, 2025 8:00 PM Eastern Daylight Time Dr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing Facility Share Advanced bioprocessing solutions from Thermo Fisher to support large-scale production and global access to cell and gene therapies WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea ...

Accessibility StatementSkip Navigation About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertis ...

Core Insights - Scinai Immunotherapeutics Ltd. reported financial results for the first half of 2025, showing significant growth in revenues and a reduction in R&D expenses compared to the same period in 2024 [1][5]. Financial Summary - Revenues for the six months ended June 30, 2025, totaled $773 thousand, up from $284 thousand in the same period of 2024, indicating growth in the CDMO business [5]. - R&D expenses decreased to $1,237 thousand from $2,788 thousand year-over-year, primarily due to lower wage and facility allocations [5]. - Marketing, general, and administrative expenses increased to $1,256 thousand from $1,003 thousand, attributed to share-based payments and an insurance reimbursement recorded in 2024 [5]. - The net loss narrowed to $4,134 thousand from $4,481 thousand, reflecting higher revenues and lower R&D expenses [5]. - As of June 30, 2025, cash and cash equivalents were $989 thousand, with an additional $4.2 million raised in July and August 2025, enhancing the cash position [5]. Business Update - Scinai Bioservices, the CDMO unit, generated $421 thousand in revenues in the first half of 2025, with total service orders reaching $1.0 million [5]. - The company is advancing its anti-IL-17 NanoAb program, focusing on treatments for psoriasis with two product profiles in development [5]. - Scinai plans to apply for up to €15 million in grant financing under the EU STEP program to fund Phase 1/2a clinical trials, with a decision expected in Q1 2026 [5]. - In 2025, the company filed patents for four additional NanoAbs and is exercising its exclusive option to license them [5]. - The company signed an option agreement to acquire PinCell srl, with a related €12 million FENG grant application under review [5].

Core Insights - The company reported strong interim results for the first half of 2025, with revenue reaching RMB831.9 million and a gross profit margin of 40.8%, reflecting a significant improvement in operational efficiency and business structure optimization [1] - The CRO business experienced a positive growth trajectory, with revenue increasing by approximately 9.6% year-over-year, driven by a recovery in global biopharmaceutical investments and a surge in domestic innovative drug transactions [2] - The company has successfully expanded its client base, serving 1,669 CRO clients, including all top 10 global pharmaceutical companies, with overseas revenue contributing approximately 85% [3] Financial Performance - Revenue for the first half of 2025 was RMB831.9 million, with a gross profit of RMB339.4 million, leading to a gross profit margin increase of 6.3 percentage points [1] - Net profit amounted to RMB148.6 million, a 3.1% increase year-over-year, while adjusted non-IFRS net profit rose by 9.1% to RMB183.5 million [1] - Langhua Pharmaceutical's revenue reached RMB409.0 million, with an adjusted gross profit margin of 37.9%, reflecting a year-on-year increase of 7.9 percentage points [8] CRO Business Development - The CRO business saw a revenue increase to RMB422.8 million, with adjusted gross profit rising to RMB194.6 million, attributed to improved operational efficiency and a robust order backlog [2] - New modalities accounted for approximately 15% of CRO revenue, growing nearly 19% year-on-year, indicating a shift towards innovative drug development [4] - The company has integrated AI technology into its drug discovery platform, contributing to nearly 10% of total CRO revenue [5][6] CDMO and CMC Business - The company is enhancing its CDMO capabilities through the acquisition of Langhua Pharmaceutical, which has initiated new commercialization projects [7] - Langhua Pharmaceutical's adjusted gross profit margin improved significantly due to structural optimization in its CDMO business [8] - The CMC business has shown significant profitability improvements, with a focus on synthesis and analysis operations [10] Investment and Portfolio Management - The company successfully exited investments from various portfolio companies, generating total proceeds of nearly RMB76.5 million [12] - As of June 30, 2025, the company had invested in 93 portfolio companies, with a significant portion located in North America [12][13] - The company is actively participating in establishing an RMB-denominated fund to support biopharmaceutical ventures [15] Infrastructure and Workforce - As of June 30, 2025, the company employed 2,085 staff, with a significant number dedicated to CRO R&D [16] - The company has expanded its facilities, including a new headquarters in Shanghai and multiple parks for R&D and production [17][18] - The Shanghai Supercomputing Center has been operational, supporting advanced drug discovery computations [19] Strategic Vision - The company aims to strengthen the synergy between its CRO and CDMO businesses, enhancing its one-stop innovative drug R&D platform [20] - Future plans include boosting revenue growth and profitability through strategic partnerships and improved operational efficiencies [11][22]

Core Insights - EUROAPI has appointed Frédéric Robert as Chief Commercial Officer to enhance its API Solutions and CDMO activities, aligning with the FOCUS-27 transformation plan [1][3] - The new role will focus on creating synergies between API and CDMO operations, delivering the FOCUS-27 sales plan, and redefining the global sales strategy [2][3] Company Overview - EUROAPI is a leading producer of active pharmaceutical ingredients (API) and operates as a contract development and manufacturing organization (CDMO) [1][5] - The company offers approximately 200 products and has strong R&D capabilities with six manufacturing sites in Europe, serving customers in over 80 countries [5][6] Leadership Background - Frédéric Robert brings over 25 years of experience in the pharmaceutical industry, having held senior roles at companies like Aptar, Fareva, and NAOS Bioderma [3][4] - His expertise includes overseeing commercial operations across Europe and North America, providing a comprehensive understanding of the API and CDMO value chain [3][4]

Financial Performance - As of March 31, 2025, the company had cash and cash equivalents and short-term deposits of $1,018 thousand, a decrease from $1,964 thousand as of March 31, 2024 [3] - Revenues for the three months ended March 31, 2025, totaled $586 thousand, reflecting a year-over-year increase driven by a higher number of contracts executed in the CDMO business [7] - R&D expenses for the same period amounted to $1,296 thousand, down from $1,568 thousand in 2024, primarily due to lower wages and reduced direct R&D expenses [7] - Marketing, general and administrative expenses were $500 thousand, slightly up from $484 thousand in the same period last year [7] - The net loss for the three months ended March 31, 2025, was $1,557 thousand, an improvement from a net loss of $2,159 thousand for the same period in 2024 [7] Business Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing innovative biological drug candidates for inflammation and immunology-related diseases [4] - The company operates two business units: one for in-house development of biological therapeutic products and another as a boutique CDMO providing various drug development services [4] - The CDMO unit began generating revenues in the second quarter of 2024, with full-year revenues for 2024 reported at $658 thousand [7]

Core Insights - BioHarvest Sciences Inc. has secured a new contract for developing a plant-based fragrance compound, targeting the multi-billion-dollar fragrance and scents market [1][3] - The contract will utilize the company's proprietary Botanical Synthesis technology and advanced AI-assisted research capabilities to identify specific plant species for efficient production [2][4] - The agreement includes milestone-based payments and a non-disclosure agreement for the initial stage of the project [3] Company Overview - BioHarvest is a leader in Botanical Synthesis, leveraging patented technology to grow plant-based compounds without the need for the actual plants [5] - The company operates in two major business verticals: as a contract development and manufacturing organization (CDMO) and as a creator of proprietary nutraceutical health and wellness products [5][6] - The CEO emphasized the contract's potential to expand the company's reach into the high-value fragrance space while contributing to the conservation of threatened plant species [4]

Core Insights - BioHarvest Sciences Inc. has transitioned to stage two of its partnership with a pharmaceutical company, marking a significant milestone in the development of plant-derived biological materials for approved drugs [1][4] - The transition involves cultivating specific plant cells in liquid media within small-scale bioreactors, which is a crucial step towards commercial scalability [2][5] Group 1 - Stage one focused on identifying and working with specific plant cells to produce targeted phyto-medicinal compounds using solid media in petri dishes [4][5] - Stage two represents a shift to liquid media cultivation in small-scale bioreactors, which is essential for scaling up production [5][6] - Successful completion of stage two will lead to stage three, where cells will be grown in large-scale industrial bioreactors, with current operations already utilizing bioreactors of 1,200 liters and above [6] Group 2 - The company's mission is to discover, develop, manufacture, and democratize life-changing plant compounds that promote health and wellness while preserving the planet [7] - The transition from stage one to stage two validates the company's work and demonstrates the effectiveness of its botanical synthesis platform, which has been developed over 17 years [8]

Core Insights - BioHarvest Sciences Inc. has successfully progressed its CDMO contract with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, validating its Botanical Synthesis platform for developing active pharmaceutical compounds [1][4] Group 1: Contract Development and Manufacturing Organization (CDMO) Progress - Stage 1 of the contract, initiated in early 2024, involved sourcing plants to develop a compound for an approved drug product, which has now been completed successfully [2] - The successful completion of Stage 1 indicates that the research team isolated and multiplied the target plant cells using the proprietary Botanical Synthesis platform [2] - Stage 2 will focus on delivering sufficient biomass for testing and developing optimal growing conditions, leading to small and medium-scale production and eventually commercial volume production [3] Group 2: Company Statements and Future Outlook - The CEO of BioHarvest expressed excitement about advancing to Stage 2, highlighting the milestone as a validation of the platform's versatility and its potential to provide cost-effective alternatives to traditional sourcing methods [4] - The Chairman of the CDMO Division noted that Stage 1 carried the highest technical risk, and its successful completion demonstrates the platform's capability to address a wide range of molecule families, with Stage 2 expected to have a higher probability of success [4]

Core Insights - WuXi Biologics has received the 2025 CDMO Leadership Awards in the "Biologics - Global" category, marking its eighth consecutive year of recognition for excellence in various areas [1][2][3] Company Achievements - The company has demonstrated a commitment to advancing integrated technology platforms, significantly shortening the development time for monoclonal antibody projects to 9 months, with a recent autoimmune disease project completed in just 6 months [2] - WuXi Biologics has scaled its manufacturing capacity from 4,000 to 16,000 liters using single-use technology (SUT), achieving a 99% success rate from 2022 to 2024 [2] - The company has maintained a 100% success rate in pre-approval inspections (PAI) and has passed over 40 inspections by global regulatory agencies, including 22 by the FDA and EMA [2] Leadership and Recognition - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the importance of the award as a reflection of the trust from global partners and the dedication of the team [3] - The CDMO Leadership Awards evaluated 210 CDMOs based on third-party research, recognizing top performers in four categories across three service regions [3] Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [4] - The company employs over 12,000 skilled employees across multiple countries, supporting 817 integrated client projects, including 21 in commercial manufacturing [5] Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone of long-term growth, driving green technology innovations and achieving excellence in Environment, Social, and Governance (ESG) practices [6]